Pliant Therapeutics (PLRX) News Today $1.42 -0.02 (-1.04%) As of 03:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Vanguard Group Inc. Has $42.52 Million Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX)Vanguard Group Inc. reduced its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) by 8.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,228,755 shares of the company's stock after seApril 14 at 3:21 AM | marketbeat.comPliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International ConferenceApril 7, 2025 | globenewswire.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Sees Significant Growth in Short InterestPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 3,980,000 shares, an increase of 21.0% from the February 28th total of 3,290,000 shares. Approximately 7.0% of the company's shares are sold short. Based on an average daily volume of 2,470,000 shares, the days-to-cover ratio is currently 1.6 days.April 4, 2025 | marketbeat.comPliant Therapeutics: An Activist On DeckApril 3, 2025 | seekingalpha.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Hold" by BrokeragesPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has earned a consensus recommendation of "Hold" from the twelve research firms that are presently covering the company, Marketbeat.com reports. Twelve equities research analysts have rated the stock with a hold rating. The average 12 monthApril 3, 2025 | marketbeat.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 28, 2025 | prnewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRXMarch 26, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 23, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - PLRXMarch 21, 2025 | markets.businessinsider.comPliant Therapeutics (NASDAQ:PLRX) Receives Neutral Rating from HC WainwrightHC Wainwright reiterated a "neutral" rating on shares of Pliant Therapeutics in a research report on Tuesday.March 19, 2025 | marketbeat.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 19, 2025 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 18, 2025 | markets.businessinsider.comPliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor TypesMarch 18, 2025 | benzinga.comPliant Therapeutics announces interim Phase 1 data from PLN-101095March 17, 2025 | markets.businessinsider.comPliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid TumorsMarch 17, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 15, 2025 | globenewswire.comPliant Therapeutics, Inc.: Pliant Therapeutics Adopts Limited Duration Stockholder Rights AgreementMarch 13, 2025 | finanznachrichten.deSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 13, 2025 | prnewswire.comPliant Therapeutics Adopts Limited Duration Stockholder Rights AgreementMarch 13, 2025 | globenewswire.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 9, 2025 | globenewswire.comHC Wainwright Issues Optimistic Estimate for PLRX EarningsPliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2025 EPS estimates for Pliant Therapeutics in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst E. Arce now anticipates that the company will postMarch 8, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Hold" from AnalystsPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) has received a consensus rating of "Hold" from the twelve analysts that are currently covering the company, MarketBeat Ratings reports. Twelve equities research analysts have rated the stock with a hold rating. The average 12 month price obMarch 8, 2025 | marketbeat.comEquities Analysts Offer Predictions for PLRX FY2029 EarningsPliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Stock analysts at HC Wainwright upped their FY2029 EPS estimates for Pliant Therapeutics in a report released on Tuesday, March 4th. HC Wainwright analyst E. Arce now anticipates that the company will earn $1.80 per share for the year, up frMarch 7, 2025 | marketbeat.comCantor Fitzgerald Predicts PLRX FY2025 EarningsPliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Pliant Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos expeMarch 7, 2025 | marketbeat.comLeerink Partnrs Brokers Raise Earnings Estimates for PLRXPliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Equities research analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for Pliant Therapeutics in a research note issued to investors on Monday, March 3rd. Leerink Partnrs analyst F. Khurshid now anticipates that the company wilMarch 7, 2025 | marketbeat.comLeerink Partnrs Downgrades Pliant Therapeutics (NASDAQ:PLRX) to HoldLeerink Partnrs lowered shares of Pliant Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday.March 6, 2025 | marketbeat.comINVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsMarch 5, 2025 | globenewswire.comCitigroup Has Lowered Expectations for Pliant Therapeutics (NASDAQ:PLRX) Stock PriceCitigroup reduced their price target on shares of Pliant Therapeutics from $4.00 to $1.50 and set a "neutral" rating on the stock in a research report on Tuesday.March 5, 2025 | marketbeat.comHC Wainwright Reaffirms Neutral Rating for Pliant Therapeutics (NASDAQ:PLRX)HC Wainwright reiterated a "neutral" rating on shares of Pliant Therapeutics in a report on Tuesday.March 5, 2025 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Given New $3.00 Price Target at Royal Bank of CanadaRoyal Bank of Canada lowered their price target on Pliant Therapeutics from $4.00 to $3.00 and set a "sector perform" rating for the company in a report on Tuesday.March 5, 2025 | marketbeat.comLeerink Partners Downgrades Pliant Therapeutics (PLRX)March 5, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRXMarch 4, 2025 | prnewswire.comPliant Therapeutics (NASDAQ:PLRX) Given Neutral Rating at Cantor FitzgeraldCantor Fitzgerald reiterated a "neutral" rating on shares of Pliant Therapeutics in a research note on Tuesday.March 4, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Pliant Therapeutics (PLRX) and Capricor Therapeutics (CAPR)March 4, 2025 | markets.businessinsider.comPliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $3.00 at Wells Fargo & CompanyWells Fargo & Company reduced their price target on Pliant Therapeutics from $4.00 to $3.00 and set an "equal weight" rating for the company in a research note on Tuesday.March 4, 2025 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Earns Hold Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "hold" rating and issued a $10.00 target price on shares of Pliant Therapeutics in a report on Tuesday.March 4, 2025 | marketbeat.comPliant Therapeutics shares rise on better-than-expected Q4 earningsMarch 4, 2025 | in.investing.comPliant Therapeutics Reports Q4 2024 Results and UpdatesMarch 3, 2025 | tipranks.comPliant Therapeutics (NASDAQ:PLRX) Issues Quarterly Earnings Results, Beats Estimates By $0.16 EPSPliant Therapeutics (NASDAQ:PLRX - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.98) by $0.16.March 3, 2025 | marketbeat.comPliant Therapeutics (NASDAQ:PLRX) Announces Quarterly Earnings ResultsPliant Therapeutics (NASDAQ:PLRX - Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.16.March 3, 2025 | marketbeat.comPliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial ResultsMarch 3, 2025 | globenewswire.comStifel Nicolaus Downgrades Pliant Therapeutics (NASDAQ:PLRX) to HoldStifel Nicolaus downgraded Pliant Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday.March 3, 2025 | marketbeat.comPliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung DisorderMarch 3, 2025 | benzinga.comLeerink Partners Downgrades Pliant Therapeutics (NASDAQ:PLRX) to Market PerformLeerink Partners cut Pliant Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Monday.March 3, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXMarch 3, 2025 | prnewswire.comPliant Therapeutics Shares it 52-Week Low After Phase2b Trial DiscontinuedMarch 3, 2025 | marketwatch.comPliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary FibrosisMarch 3, 2025 | globenewswire.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Sees Significant Drop in Short InterestPliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 3,540,000 shares, a drop of 51.0% from the January 31st total of 7,230,000 shares. Based on an average trading volume of 1,500,000 shares, the short-interest ratio is presently 2.4 days.March 2, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRXFebruary 25, 2025 | prnewswire.comPLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law FirmFebruary 20, 2025 | prnewswire.com Remove Ads Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address PLRX Media Mentions By Week PLRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PLRX News Sentiment▼0.890.80▲Average Medical News Sentiment PLRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PLRX Articles This Week▼14▲PLRX Articles Average Week Remove Ads Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMLX News RNAC News CKPT News TECX News PHAT News RGNX News BNTC News ALLO News ORKA News TKNO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PLRX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLRX Stock Free PLRX Stock Alerts